Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

DNA origami offers more accurate imaging in the fight against pancreatic cancer

2.

Early palliative care billing up from 2010 to 2019 for advanced cancer

3.

Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma

4.

Updates from the 2022 WHO classification of kidney epithelial tumors

5.

The acceptance of innovative hormonal therapy for advanced prostate cancer is racialized.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot